

Applicants: D. E. Yelton and M. J. Rosok
Serial No.: 08/905,293
Filed: August 1, 1997
Page 2

In the Specification

At page 14, lines 10 and lines 13-14 and at page 41, line 13, please update the address of the ATCC by deleting "12301 Parklawn Drive, Rockville, MD 20852" and inserting 10801

C' University Boulevard, Manassas, Virginia, 20110-2209 USA—.

At page 41, line 13 and at page 45, line 21, please update the address of the ATCC by deleting "Rockville, MD" and inserting Manassas, VA.

In the Claims

Please amend claims 2, 13, 14, 17, 18, 21 and 22 as follows:

C² 2. (Amended) A method for inhibiting immunoglobulin-induced toxicity resulting from immunoglobulin immunotherapy in a subject comprising administering a structurally altered antibody to the subject, the structurally altered antibody comprising a variable region and a constant region, multiple toxicity associated domains in the constant region being modified so as to render the constant region unable to mediate an [ADCC] antibody dependent cellular cytotoxicity response or activate complement thereby inhibiting immunoglobulin-induced toxicity resulting from immunotherapy.

C³ 13. (Amended) The method of claim 2, wherein the antibody is a monoclonal antibody BR96 produced by the hybridoma [having the identifying characteristics of] HB 10036 as deposited with the ATCC.

14. (Amended) The method of claim 2, wherein the antibody is a chimeric antibody ChiBR96 produced by the hybridoma [having the identifying characteristics of] HB 10460 as deposited with the ATCC.

Applicants: D. E. Yelton and M. J. Rosok

Serial No.: 08/905,293

Filed: August 1, 1997

Page 3

C4
17. (Amended) The method of claim 1 or 5, wherein the immunoglobulin is a monoclonal antibody BR96 produced by the hybridoma [having the identifying characteristics of] HB 10036 as deposited with the ATCC.

18. (Amended) The method of claim 1 or 5, wherein the immunoglobulin is a chimeric antibody ChiBR96 produced by the hybridoma [having the identifying characteristics of] HB 10460 as deposited with the ATCC.

C5
21. (Amended) The method of claim 3, 4, or 6, wherein the Ig fusion protein [is a derivative] comprises the antigen binding site of monoclonal antibody BR96 produced by the hybridoma [having the identifying characteristics of] HB 10036 as deposited with the ATCC.

22. (Amended) The method of claim 3, 4, or 6, wherein the Ig fusion protein [is a derivative] comprises the antigen binding site of chimeric antibody ChiBR96 produced by [the hybridoma having the identifying characteristics of] HB 10460 as deposited with the ATCC.

REMARKS

I. Claims Pending in The Application:

Claims 1-22 and 28-31 are pending in this application. Claims 2, 13, 14, 17, 18, 21 and 22 were amended. In view of the following remarks and the changes hereinabove, Applicants respectfully request that the Patent Office reconsider and withdraw the various grounds for objection and rejection set forth in the Office Action. The amendments to the claims introduce no new matter. At page 23, lines 23-27, the specification teaches that derivative molecules are those which retain the functional property of the polypeptide, namely, such molecules will still permit the binding of the polypeptide to the BR96 antigen or portions thereof.